Uncovering Outcome Disparities of β2 Adrenergic Agonists in Blacks: A Systematic Review

Jerome, Rebecca N; Pulley, Jill M.; Sathe, Nila A; Krishnaswami, Shanthi; Dickerson, Alyssa B.; Worley, Katherine; Lima, Maria F.; Wilkins, Consuelo H.

doi:10.1016/j.jnma.2020.07.001

Cited by 4 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical outcomes from multiple randomised controlled trials (RCT) and cohort studies on LABAs responses across different ethnicities are inconclusive ( 77 ). Several Cochrane reviews of RCTs have found seriously increased risk of disease deterioration in African Americans associated with LABA therapy compared to other population groups ( 78 – 81 ).…”

Section: Long-acting β 2 -Agonistsmentioning

confidence: 99%

“…The β 2 -adrenergic receptor gene (ADRB2), a receptor target for beta-agonist therapy has been vigorously investigated ( Table 1 ) ( 67 , 75 , 77 , 84 , 85 ). ADRB2 is intronless, yet a polymorphic gene with more than 49 different genetic variants in multi-ethnic asthma cohorts evaluated to date ( 86 – 88 ).…”

Section: Genetic Variants In the β 2 -Adrenergic R...mentioning

confidence: 99%

See 1 more Smart Citation

Immunogenetics and pharmacogenetics of allergic asthma in Africa

et al. 2023

View full text Add to dashboard Cite

Asthma is a common chronic condition in children and in an African setting is often highly prevalent in urban areas as compared to rural areas. Asthma is a heritable disease and the genetic risk is often exacerbated by unique localised environmental factors. The Global Initiative for Asthma (GINA) recommendation for the control of asthma includes inhaled corticosteroids (ICS) alone or together with short-acting β2-agonists (SABA) or long-acting β2-agonists (LABA). While these drugs can relieve asthma symptoms, there is evidence of reduced efficacy in people of African ancestry. Whether this is due to immunogenetics, genomic variability in drug metabolising genes (pharmacogenetics) or genetics of asthma-related traits is not well defined. Pharmacogenetic evidence of first-line asthma drugs in people of African ancestry is lacking and is further compounded by the lack of representative genetic association studies in the continent. In this review, we will discuss the paucity of data related to the pharmacogenetics of asthma drugs in people of African ancestry, mainly drawing from African American data. We will further discuss how this gap can be bridged to improve asthma health outcomes in Africa.

show abstract

Section: Long-acting β 2 -Agonistsmentioning

confidence: 99%

Section: Genetic Variants In the β 2 -Adrenergic R...mentioning

confidence: 99%

Immunogenetics and pharmacogenetics of allergic asthma in Africa

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A systematic review has reported that the ADRB2 encoding the beta2 adrenergic receptor is the most-studied gene on the pharmacogenetics of the bronchodilator response [ 23 ]. Several studies have found associations with three non-synonymous genetic variants, rs1042713 (Arg16Gly), rs1042714 (Gln27Glu), and rs180888 (Thr164Ile) with the BDR in children and adults with asthma [ 24 , 25 , 26 , 27 , 28 , 29 ] although these results are still controversial [ 30 , 31 , 32 , 33 ] ( Table 1 ).…”

Section: Candidate Genes Studies Linked To Therapeutic Response Of Asthmamentioning

confidence: 99%

Genetic Determinants of Poor Response to Treatment in Severe Asthma

Figueiredo

Costa

Figueiredo

et al. 2021

IJMS

View full text Add to dashboard Cite

Severe asthma is a multifactorial disorder with marked phenotypic heterogeneity and complex interactions between genetics and environmental risk factors, which could, at least in part, explain why during standard pharmacologic treatment, many patients remain poorly controlled and at an increased risk of airway remodeling and disease progression. The concept of “precision medicine” to better suit individual unique needs is an emerging trend in the management of chronic respiratory diseases. Over the past few years, Genome-Wide Association Studies (GWAS) have revealed novel pharmacogenetic variants related to responses to inhaled corticosteroids and the clinical efficacy of bronchodilators. Optimal clinical response to treatment may vary between racial/ethnic groups or individuals due to genetic differences. It is also plausible to assume that epigenetic factors play a key role in the modulation of gene expression patterns and inflammatory cytokines. Remarkably, specific genetic variants related to treatment effectiveness may indicate promising pathways for novel therapies in severe asthma. In this review, we provide a concise update of genetic determinants of poor response to treatment in severe asthma and future directions in the field.

show abstract

“…Smooth muscles spasm is controlled by β 2 agonist and short-acting beta-agonists can provide quick relief of asthma symptoms and prevent allergen-induced bronchoconstriction and are approved for clinical use in asthma. Most of beta-agonists cannot be used more than two times per week for shortness of breath and long-acting beta-agonists are used in combination with a corticosteroid 7 8. Therefore, a new applicable drug design is necessary and higenamine can be used as bronchodilator and β 2 adrenoreceptor agonist that was used and introduced as effective treatment for allergic asthma.…”

Section: Introductionmentioning

confidence: 99%

Bronchodilatory Effect of Higenamine as Antiallergic Asthma Treatment

Nasab

Athari

et al. 2022

Journal of Investigative Medicine

View full text Add to dashboard Cite

Asthma is a complex airway disease that affects more than 350 million humans worldwide. Allergic asthma symptoms are induced by Th2 immune response with the release of cytokines and allegro-inflammatory mediators that amplify the inflammatory response, airway hyper-responsiveness (AHR) and hyperproduction of mucus. Higenamine, as a chemical compound, is a β2 adrenoreceptor agonist and can be used as bronchodilator in allergic asthma.BALB/c mice were allocated in four groups and then allergic asthma was induced in three groups. One of the asthmatic groups was treated with albuterol and other one was treated with higenamine. At least, methacholine challenge to determine the AHR, measurement of cytokines, total immunoglobulin E (IgE), LTB4 and LTC4 levels, evaluation of gene expression of Muc5ac, Muc5b, Agr2 and Arg1, and histopathological study were done.Higenamine treatment reduced AHR, interleukin (IL)-4, IL-13 levels, mRNA expression of MUC5ac, MUC5b, Arg1 and Agr2, goblet cell hyperplasia and mucus hypersecretion. Higenamine had no significant effect on IL-5, interferon-γ (INF-γ), IgE, LTB4, LTC4 levels and eosinophilic inflammation in lung tissue.Higenamine treatment controls asthma acute attack and breathlessness and can be used as asthma treatment with control of AHR and decrease of airflow obstruction and mucus hypersecretion and had allegro-immune-regulatory effect. But higenamine treatment had no notable effect on the inflammation and inflammatory factors.

show abstract

Uncovering Outcome Disparities of β2 Adrenergic Agonists in Blacks: A Systematic Review

Cited by 4 publications

References 36 publications

Immunogenetics and pharmacogenetics of allergic asthma in Africa

Immunogenetics and pharmacogenetics of allergic asthma in Africa

Genetic Determinants of Poor Response to Treatment in Severe Asthma

Bronchodilatory Effect of Higenamine as Antiallergic Asthma Treatment

Contact Info

Product

Resources

About